Phase 1b JAVELIN solid tumor investigation employed a PD-L1 inhibitor known as Avelumab to manage patients with metastatic breast cancer, including 58 cases of triple-negative breast cancers (TNBCs). This evidence concerns the gene CD274 and triple-negative breast carcinoma.